Monday, 16 Sep 2019

You are here

Benefits vs Harms for Osteoporosis Drug Continuation or Discontinuation

While it is clear that long-term bisphosphonate therapies reduce fracture risk in women with osteoporosis, it is unclear how to counter-balance these benefits against rare serious harms and how to optimize therapeutic benefits with appropriate drug holidays.

A systematic analysis of 48 studies compared long-term osteoporosis drug treatment (ODT) (>3 years) versus control versus ODT continuation versus durg discontinuation, to examine incident fractures or harms.

In women with osteoporosis, 4 years of alendronate reduced clinical fractures (hazard ratio [HR], 0.64 [95% CI, 0.50 to 0.82]) and radiographic vertebral fractures (both moderate SOE), whereas 4 years of raloxifene reduced vertebral but not nonvertebral fractures. In women with osteopenia or osteoporosis, 6 years of zoledronic acid reduced clinical fractures (HR, 0.73 [CI, 0.60 to 0.90]), including nonvertebral fractures (high SOE) and clinical vertebral fractures (moderate strength of evidence - SOE).

Long-term bisphosphonates showed an increased risk for atypical femoral fractures and osteonecrosis of the jaw (both low SOE). In women with unspecified osteoporosis status, 5 to 7 years of hormone therapy reduced clinical fractures (high SOE), including hip fractures (moderate SOE), but increased serious harms.

After 3 to 5 years of treatment, bisphosphonate continuation versus discontinuation reduced radiographic vertebral fractures (zoledronic acid; low SOE) and clinical vertebral fractures (alendronate; moderate SOE) but not nonvertebral fractures (low SOE).

Trials and data in men with clinical fracture data were sparse.

No trials compared sequential treatments or different durations of drug holidays.

It appears that long-term bisphosphonate treatment may increase risk for rare adverse events, and continuing treatment beyond 3 to 5 years may also reduce the risk for fractures.

Until there are well designed trials informing us on the magnitude of benefit vs. risk with drug holidays of varying duration, the decision to continue or discontinue ODT must be based on the individuals risk for future fracture. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Need for Pre-operative Hyperglycemia Testing Prior to Total Joint Replacement

JAMA reports on a large Medicare cohort study showing that amongst patients undergoing total joint replacement (TJR), preoperative HbA1c testing was performed in 26% to 43% of patients with diabetes and in only 5% of those without diabetes. Importantly research has shown that an elevated HbA1c level is associated with postoperative complications.

Weight Loss Cuts Hospital Stays for Obese TKA Patients

Morbidly obese patients who lost 20 lbs before total knee arthroplasty (TKA) cut their hospital stays by about 1 day, and were 76% less likely to have an extended hospital stay, research showed. 

High-Dose Vitamin D: No Help for Bone Health

Vitamin D might not be much help for strengthening bones among healthy adults without osteoporosis, Canadian researchers reported, even at doses far higher than recommended daily allowances. In a clinical trial assessing three levels of daily vitamin D supplementation -- 400 IU, 4,000 IU, and 10,000 IU -- radial volumetric bone mineral density was significantly lower among those (ages 55-70) taking higher doses for 3 years, according to Steven Boyd, PhD, of the University of Calgary in Canada, and colleagues.

Osteoporosis Tx: Good for Bones, but Not for Cutting Death Risk

Osteoporosis treatments were not linked with reduced overall mortality, according to a meta-analysis of placebo-controlled trial data.

Looking at data from 38 clinical trials, there was no significant association found between all drug-based osteoporosis treatments and overall mortality rate (risk ratio 0.98, 95% CI 0.91-1.05), reported Steven Cummings, MD, of the San Francisco Coordinating Center, and colleagues.

Bisphosphonate Use Associated with Reduced Mortality

The Journal of Bone and Mineral Research (JBMR) has published a report showing that a reduction in the rate of bone loss by nitrogen bisphosphonates was associated with a 40% lower mortality risk.

Accelerated bone loss has been shown to be an independent predictor of mortality risk, but the relationship between bisphosphonates, bone loss, and mortality is unknown.